ImmunoCellular Therapeutics, Ltd Licenses Mesothelin Cancer Antigen from Johns Hopkins University

Published: Feb 29, 2012

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC) today announced that it has entered into an agreement with The Johns Hopkins University (JHU) under which JHU has granted the Company an exclusive, worldwide license to intellectual property surrounding the tumor-associated antigen mesothelin, which is highly expressed in pancreatic cancer, ovarian cancer and mesothelioma. The terms of the agreement were not disclosed.

Back to news